Research Progress on the Chemical Composition， Pharmacological Effects and Toxicology of Acorus tatarinowii Schott

doi:10.2095-3593.2026.030006

Abstract

Abstract: Acorus tatarinowii Schott， as a traditional Chinese medicinal material， has a long history of medical use. In recent years， significant progress has been made in the research on its chemical composition， pharmacological effects， and toxicology. This paper systematically reviews the chemical composition， multi-target pharmacological mechanisms， and current status of toxicological research on Acorus tatarinowii Schott， aiming to provide a scientific basis for its clinical rational application and quality standardization. Chemical composition analysis shows that the main active component of Acorus tatarinowii Schott is volatile oil， with the highest content of β-asarone， and it also contains various active substances such as flavonoids， alkaloids， and polysaccharides. Pharmacological research shows that Acorus tatarinowii Schott has significant neuroprotective effects and can improve cognitive function by regulating neurotransmitters， antioxidant， anti-inflammatory， and inhibiting cell apoptosis. Its cardiovascular protective effects involve inhibiting inflammatory responses， promoting angiogenesis， and improving energy metabolism. In addition， Acorus tatarinowii Schott also has multiple pharmacological activities such as antimicrobial， antioxidant， anticancer， and immunomodulatory effects. Toxicological studies have shown that Acorus tatarinowii Schott has high safety in short-term use， but its main active component， β-asarone， has a certain dose-dependent toxicity， and further systematic assessment is needed to identify potential risks. Future research should focus on standardizing the composition， elucidating the material basis of pharmacological effects of Acorus tatarinowii Schott， and promoting the clinical translation， thereby advancing its rational application and development in the fields of nervous system and cardiovascular diseases.

Key words: font-size:medium, ">Acorus tatarinowii Schott； Volatile oil； Chemical composition； Pharmacological effects； Toxicology； Molecular mechanism

CLC Number:

WEN Qinghui, GUO Shujin. Research Progress on the Chemical Composition， Pharmacological Effects and Toxicology of Acorus tatarinowii Schott[J]. CHINESE JOURNAL OF DRUG EVALUATION, 2026, 43(1): 50-50-55.

References

[1] 国家药典委员会. 中华人民共和国药典(2025年版)[S]. 北京：中国医药科技出版社， 2025.
     [2] 支晓娟校. 神农本草经 [M]. 广州：广东科技出版社， 2022：8.
     [3] 邱路雅，杨刚，金琼，等. 石菖蒲根茎化学成分及抗炎活性研究[J]. 中草药， 2022， 53（15）：4617-4624.
     [4] 李鹏辉，孙瑜，冯小龙，等. 石菖蒲抗癫痫的药理机制研究进展[J]. 中国实验方剂学杂志， 2022， 28（18）：261268.
     [5] 石坚宏，姬丽婷，骆启晗，等. 石菖蒲化学成分、药理作用及质量标志物预测分析研究进展[J]. 中成药， 2021， 43（5）：1286-1290.
     [6] 郑甜甜，谭娟娟，张惠钰. 基于网络药理学和实验验证探究石菖蒲挥发油抗抑郁的作用机制[J]. 天然产物研究与开发， 2025， 37(1)：159.
     [7] 谢芳，刘智勇，陈惠云. 石菖蒲挥发油成分的气相色谱-质谱实验结果分析[J]. 北方药学， 2024， 21(8)：7-9.
     [8] Uebel T， Hermes L， Haupenthal S， et al. α-Asarone， β-asarone， and γ-asarone： current status of toxicological evaluation[J]. J Appl Toxicol， 2021， 41(8)：1166-1179.
     [9] 乐颖娜，张金莲，钟凌云，等. 石菖蒲炮制的历史沿革、化学成分及神经药理作用研究进展[J]. 2025， 56 (11)：4115-4120.
     [10] Al-Mijalli SH， Mrabti HN， Abdallah EM， et al. Acorus calamus as a promising source of new antibacterial agent against Pseudomonas aeruginosa and Staphylococcus aureus： deciphering volatile compounds and mode of action[J]. Microb Pathog， 2025， 200：107357.
     [11] Hu Y， Zhao Y， Mao Z， et al. Inhalation of Acori tatarinowii Rhizoma essential oil alleviates dyskinesia in Parkinson′s disease rats through the regulation of neuroinflammation[J]. J Ethnopharmacol， 348：119705.
     [12] Assaggaf H， Jeddi M， Mrabti HN， et al. Design of three-component essential oil extract mixture from Cymbopogon flexuosus， Carum carvi， and Acorus calamus with enhanced antioxidant activity[J]. Sci Rep， 2024， 14(1)：9195.
     [13] Ibdah M， Hino S， Nawade B， et al. Identification and characterization of three nearly identical linalool/nerolidol synthase from Acorus calamus[J]. Phytochemistry， 2022， 202：113318.
     [14] Huang L， Feng Z， Xiang J， et al. Anti-inflammatory compounds from the rhizome of Acorus calamus var. angustatus Besser and their mechanism[J]. Nat Prod Res， 2024， 38(20)：3669-3675.
     [15] Wang J， Zhang Y， Xu X， et al. ASP2-1， a polysaccharide from Acorus tatarinowii Schott， inhibits osteoclastogenesis via modulation of NFATc1 and attenuates LPS-induced bone loss in mice[J]. Int J Biol Macromol， 2020， 165(Pt B)：2219-2230.
     [16] Zhong J， Qiu X， Yu Q， et al. A novel polysaccharide from Acorus tatarinowii protects against LPS-induced neuroinflammation and neurotoxicity by inhibiting TLR4-mediated MyD88/NF-κB and PI3K/Akt signaling pathways[J]. Int J Biol Macromol， 2020， 163：464-475.
     [17] Yu Q， Qiu X， Zhong J， et al. Structural identification and anti-neuroinflammatory effect of a heteropolysaccharide ATP50-3 from Acorus tatarinowii rhizome[J]. Int J Biol Macromol， 2024， 266(Pt 2)：131254.
     [18] Wu J， Zhang HL， Guo S， et al. Acori Tatarinowii Rhizoma prevents the fluoxetine-induced multiple-drug resistance of Escherichia coli against antibiotics[J]. Phytomedicine， 123：155232.
     [19] 洪永福，郭学敏，孙连娜，等. 石菖蒲中多糖成分的分析[J]. 药学实践杂志， 1998，（3）： 149-151.
     [20] Kalra S， Sachdeva H， Bhushan Pant A， et al. Acorus calamus Linn.： a novel neuroprotective approach for traumatic brain injury in Drosophila melanogaster[J]. Brain Res， 2024， 1836：148953.
     [21] Venkatesan K. Anti-amnesic and anti-cholinesterase activities of α-asarone against scopolamine-induced memory impairments in rats[J]. Eur Rev Med Pharmacol Sci， 2022， 26(17)：6344-6350.
     [22] Kalra S， Sachdeva H， Pant AB， et al. Neuroprotection in traumatic brain injury： effects of alpha-asarone and Acorus calamus extract in mice using weight drop model[J]. Naunyn Schmiedebergs Arch Pharmacol， 2025， 398(9)：11855-11867.
     [23] Ukkirapandian K， Kayalvizhi E， Udaykumar KP， et al. The neuroprotective role of acorus calamus in developmental and histopathological changes in autism-induced wistar rats[J]. Cureus， 2022， 14(9)：e29717.
     [24] Zang ZZ， Chen LM， Liu Y， et al. Uncovering the protective mechanism of the volatile oil of Acorus tatarinowii against acute myocardial ischemia injury using network pharmacology and experimental validation[J]. Evid Based Complement Alternat Med， 2021：6630795.
     [25] Lee J， Shin S， Park J， et al. Vasorelaxant effects and its mechanisms of the rhizome of Acorus gramineus on isolated rat thoracic aorta[J]. Sci Rep， 2025， 15(1)：4386.
     [26] Xiao B， Huang X， Wang Q， et al. Beta-asarone alleviates myocardial ischemia-reperfusion injury by inhibiting inflammatory response and NLRP3 inflammasome mediated pyroptosis[J]. Biol Pharm Bull， 2020， 43(7)：1046-1051.
     [27] Qiu Y， Zhao P， Xu L， et al. Therapeutic mechanisms of Acorus tatarinowii and its bioactive compounds in cardiovascular diseases： a comprehensive review[J]. Phytomedicine， 145：156988.
     [28] Sytykiewicz H， ukasik I， Goawska S. Chemical composition， anti-tyrosinase and antioxidant potential of essential oils from Acorus calamus (L.) and Juniperus communis (L.) [J]. Molecules， 2025， 30(11)：2417.
     [29] Vinotha V， Yazhiniprabha M， Jeyavani J， et al. Synthesis and characterization of cry protein coated zinc oxide nanocomposites and its assessment against bacterial biofilm and mosquito vectors[J]. Int J Biol Macromol， 2022， 208：935-947.
     [30] Mikami M， Takuya O， Yoshino Y， et al. Acorus calamus extract and its component α-asarone attenuate murine hippocampal neuronal cell death induced by l-glutamate and tunicamycin[J]. Biosci Biotechnol Biochem， 2021， 85(3)：493-501.
     [31] Bari MU， Hussain A， Aslam B， et al. Anti-arthritic appraisal of Acorus calamus L. extracts in complete Freund′s adjuvant-induced arthritic Wistar rats via regulating inflammatory cytokines and OPG/RANKL pathway[J]. Inflammopharmacology， 2026， 34（1）：381-398.
     [32] Chang H， Shao L， Tao K， et al. Exploring CCND1 as a key target of Acorus calamus against RSV infection： network pharmacology， molecular docking， and bioinformatics analysis[J]. Curr Issues Mol Biol， 2025， 47(9)：695.
     [33] Schnknecht K， Surdacka A， Rudenko L. Effectiveness of composed herbal extract in the treatment of gingivitis and oral and pharyngeal mucosa-review of studies[J]. Wiad Lek， 2021， 74(7)：1737-1749.
     [34] Liu FX， Zhang DP， Ma YM， et al. Effect of Jiawei Tongqiao Huoxue decoction in basilar artery dolichoectasia mice through yes-associated protein/transcriptional co-activator with PDZ-binding motif pathway[J]. J Ethnopharmacol， 2023， 314：116599.
     [35] Chen J， Hao W， Zhang C， et al. Explore the therapeutic composition and mechanism of schisandra chinensis-Acorus tatarinowii Schott on Alzheimer′s disease by using an integrated approach on chemical profile， network pharmacology， and UPLC-QTOF/MS-based metabolomics analysis[J]. Oxid Med Cell Longev， 2022， 7(11)：6362617.
     [36] Huang J， Xu Z， Yu C， et al. The volatile oil of Acorus tatarinowii Schott ameliorates Alzheimer′s disease through improving insulin resistance via activating the PI3K/AKT pathway[J]. Phytomedicine， 2024， 135：156168.
     [37] Malik R， Kalra S， Pooja， et al. Antioxidative and neuroprotective potential of Acorus calamus linn. and Cordia dichotoma G. Forst. In Alzheimer’s type dementia in rodent[J]. Brain Res， 2024， 1822：148616.
     [38] Zaheri AZ， Vafamand Y， Malayeri A， et al. The evaluation of the anti-inflammatory effects of Acorus calamus L. ethanolic extract on ovalbumin-induced allergic asthma in mice[J]. J Ethnopharmacol， 2025， 354：120033.
     [39] Sun Y， Bai Y， Li B， et al. β-Asaronol， the neuroactive component of Acorus tatarinowii： mitigating seizures with minimal developmental risk in dravet syndrome[J]. ACS Chem Neurosci， 2025， 16(18)：3577-3590.
     [40] Narayana DBA， Mukne A. Reporting negative Ames test results for Indian Acorus calamus L.， rhizome， extracts， and beta asarone[J]. Indian J Pharmacol， 2025， 57(5)：302-307.
     [41] He X， Chen X， Yang Y， et al. Acorus calamus var. angustatus Besser： Insight into current research on ethnopharmacological use， phytochemistry， pharmacology， toxicology， and pharmacokinetics[J]. Phytochemistry， 2023， 210：113626.
     [42] Szczeblewski P， Wróblewski M， Borzyszkowska-Bukowska J， et al. The role of centrifugal partition chromatography in the removal of β-asarone from Acorus calamus essential oil[J]. Sci Rep， 2022， 12(1)：22217.

Research Progress on the Chemical Composition， Pharmacological Effects and Toxicology of Acorus tatarinowii Schott

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	LI Xu, HE Xiaoyu, ZHAO Pinghua, SHANG Xiaoyan. Uncertainty Evaluation and Z-Value Analysis for Determination of the Content of Stilbene Glucoside in Proficiency Testing Samples of Polygonum multiflorum by HPLC [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2026, 43(1): 18-18-23.
[2]	DAI Qi, GUI Ziya, DONG Zhaowei, YE Qiaobo, LUO Xiao, ZHANG Liang. Research Progress on the Active Constituents of Cratargi Fructus and Their Mechanism of Action in Treating Nonalcoholic Fatty Liver Disease [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2026, 43(1): 39-39-45.
[3]	CHENG Qianqian, ZHANG Yali. Investigation on Medication Adherence in Elderly Patients with Multiple Chronic Diseases and Its Related Factors [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2026, 43(1): 77-77-80.
[4]	YAN Ruoxi. Analysis of Quality Management System Elements in Pharmaceutical Inspectorates from Total Quality Management Perspective [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2026, 43(1): 1-1-8.
[5]	QU Chunge, JIANG Shan, YOU Mingyu, TIAN Tian. Surface Modification of Medical Magnesium-Based Materials： Advances and Perspectives [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2026, 43(1): 9-9-13.
[6]	LIU Shuxia, ZHOU Yongkang. Research and Development Progress of Fresh Chinese Medicine [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2026, 43(1): 46-46-49.
[7]	ZHAO Chenxi, XIE Ying, YANG Liu, YANG Yabin, LI Tingting. Investigating the Mechanism of Action of Sambucus adnata Wall. in the Treatment of Bone Fracture Based on Network Pharmacology and Molecular Docking Technology [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2026, 43(1): 32-32-38.
[8]	JIA Dengying, ZHANG Jie, LI Pei, PANG Bo, FANG Xia, WANG Hongmei, ZHAO Wenfa. Advances in the Application of ICP-MS in Pharmaceutical Quality Control [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2026, 43(1): 14-14-17.
[9]	HU Bin, DONG Liang. Effects of Anlotinib Combined with TP Chemotherapy Regimen on Inflammatory Response and Tumor Markers in Patients with Advanced Non-Small Cell Lung Cancer [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2026, 43(1): 56-56-61.
[10]	HUAN Jing, NI Qi. Exploration and Reflection on the Training of Clinical Research Coordinators [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2026, 43(1): 74-74-76.
[11]	MA Zhengran, HUANG Ziyi, WANG Xiaoying, YANG Wenlong, ZHU Zhiwei. A Knowledge Graph-Based Study on the Medication Rules of Dali Ethnic Folk Empirical Prescriptions for Bi Syndrome [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2026, 43(1): 24-24-31.
[12]	WANG Fang, CHEN Lin, LI Huyu, WANG Shengchun. Clinical Study of Tacrolimus Combined with Five Vitamins and Lysine Granules in the Treatment of Pediatric Vitiligo [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2026, 43(1): 68-68-73.
[13]	LI Yong, QI Yujie, YANG Dongwei. Comparative Efficacy of Sacubitril/Valsartan Sodium versus Perindopril in Elderly Patients with HFrEF and Hypertension [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2026, 43(1): 62-62-67.
[14]	ZHANG Hanwen, HAN Ning, ZHAO Wei. Clinical Observation of Labetalol Combined with Nifedipine in the Treatment of Gestational Hypertension [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2025, 42(6): 464-464-468.
[15]	FENG Junyi, LI Ye, ZHANG Bingchang, SHI Hui, YANG Jue. Analysis of the Clinical Trial Research for Diabetes Drugs Based on the China Drug Trials Platform [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2025, 42(6): 492-492-496.